Sofie receives nod to start trial for PET tracer

By AuntMinnie.com staff writers

November 12, 2021 -- Sofie Biosciences recently received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a clinical trial for a PET radiotracer based on fibroblast activation protein inhibitor (FAPI).

The company will now lead a phase II, multicenter, single-blind, nonrandomized study of its gallium-68 FAPI-46 PET radiotracer for imaging patients with pancreatic ductal adenocarcinoma. This comes after a 30-day review with the FDA.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: